New combo aims to shrink lymphoma tumors with less chemo

NCT ID NCT05551936

Ongoing Disease control Sponsor: Vaishalee Kenkre Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug combination for people with a type of slow-growing blood cancer called follicular lymphoma that has a high tumor burden. The treatment adds tazemetostat (a targeted pill) to a standard chemo-immunotherapy regimen, but uses a shorter course of chemotherapy to reduce side effects. About 42 adults will receive the combination for up to 6 cycles. The goal is to see if this approach is safe and leads to complete remission.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULAR LYMPHOMA

Contacts and locations

Show contact details

Locations

Northwestern University

Chicago, Illinois, 60611, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
University of Illinois Cancer Center

Chicago, Illinois, 60612, United States
University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.